Insider trade report
Open the filing on sec.gov
Anavex Life Sciences Corp. (AVXL)
Nasdaq: AVXL · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2005
The companyfiscal 2025, as filed
Revenuen/a
Net income-$46.4M-7.8%
Earnings per share$-0.54-3.8%
Operating cash flow-$39.0M-26.7%
Cash$103M-22.4%
Debtn/a
Shareholders’ equity$94.9M-21.1%
Shares, diluted85.3M+2.2%
Return on equity-48.9%
The recordfrom its filings
Filings in 202667
Newest filingNov 6 · 4
Annual reportNov 25, 2025
Quarterly reportAug 28, 2026
Next report due10-K by Nov 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted28
Filer categoryLarge accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$13.0MCash from operations -$29.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.